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C A N C E R
Matching cell lines with cancer type and  
subtype of origin via mutational, epigenomic, 
and transcriptomic patterns
Marina Salvadores1, Francisco Fuster-Tormo1,2, Fran Supek1,3*
Cell lines are commonly used as cancer models. The tissue of origin provides context for understanding biological 
mechanisms and predicting therapy response. We therefore systematically examined whether cancer cell lines 
exhibit features matching the presumed cancer type of origin. Gene expression and DNA methylation classifiers 
trained on ~9000 tumors identified 35 (of 614 examined) cell lines that better matched a different tissue or cell type 
than the one originally assigned. Mutational patterns further supported most reassignments. For instance, cell lines 
identified as originating from the skin often exhibited a UV mutational signature. We cataloged 366 “golden set” cell 
lines in which transcriptomic and epigenomic profiles strongly resemble the cancer type of origin, further proposing 
their assignments to subtypes. Accounting for the uncertain tissue of origin in cell line panels can change the 
interpretation of drug screening and genetic screening data, revealing previously unknown genomic determinants 
of sensitivity or resistance.
INTRODUCTION
Cell lines are an important research tool, often used in place of 
primary cells and intact organisms to study biological processes. 
Cell lines are used for various applications such as testing drug 
metabolism and cytotoxicity, study of gene function, generation of 
artificial tissues, and synthesis of biological compounds (1). In 
cancer research, cell lines derived from tumors are commonly used 
as models, because they are presumed to carry the genomic and 
epigenomic alterations that arise in tumors (2). To understand the 
response of tumors to therapy, many studies have linked genetic 
and/or epigenetic alterations with drug response across cell line 
panels, generating datasets such as the Genomics of Drug Sensitivity 
in Cancer (GDSC) (3) and the Cancer Cell Line Encyclopedia (CCLE) 
(4). These efforts have advanced our understanding of tumor biology 
by generating a massive resource of genomic, transcriptomic, 
epigenomic, and drug response data for hundreds of cell lines (2).
As a model for cancer, cell lines are cost-effective, convenient, 
and amenable to high-throughput screening (1, 2). However, a major 
question associated with the use of cell lines is whether they are repre-
sentative of the cancer they are meant to model, which may be 
complicated by issues of misidentification (1, 2, 5).
Misidentified cell lines may lead to inconsistent conclusions across 
studies using the affected cell lines. For instance, the cell lines re-
ferred to as HEp-2 and INT 407 in the literature are commonly 
cross-contaminated with HeLa (cervical cancer) cells, rather than 
being laryngeal cancer and normal intestinal epithelium cells, re-
spectively (6, 7). Because of the potential for contamination, demon-
strating cell line identity via genetic markers is now a routine 
quality-control step. Current resources based on large-scale cancer 
cell panels are therefore largely unaffected by this issue (4).
However, even if the genetic identity of the cell line is correct, its 
properties may not match the cancer type it is meant to model. In 
particular, the tissue of origin might be incorrect. One way in which 
this error could arise is that tumors thought to originate in a cer-
tain tissue might be metastatic lesions originating from a distal site 
(8). Cell lines derived from these tumors would have a different tissue/
cell type identity than that assigned at isolation, constituting a case 
of mislabeling. It is conceivable that, also in the case of primary tu-
mors, ambiguous histological or anatomical features may cause the 
tumor type or subtype to be misdiagnosed and therefore also for a 
cell line derived from that tumor. Furthermore, the process of es-
tablishing the culture might select for a rare cell type that is not 
representative of the tumor isolate on the whole, meaning that the 
derived cell line would again effectively be mislabeled with a differ-
ent cell type (9). In addition to the initial changes upon adaptation 
to culture, cell lines evolve over time due to selection and due to ge-
netic drift, potentially diverging from the characteristics of the origi-
nating tissue (1).
Tissue and/or cell type is a key determinant of response of cul-
tured cells to a variety of experimental conditions, including drug 
exposure and genetic perturbation (10, 11). Therefore, having accu-
rate information on the tissue and cell type identity of a tumoral cell 
line is important for interpreting the experimental results obtained 
using these cell lines.
Recent work has examined cell line panels of certain cancer 
types, showing discrepancies between the features of cell lines and 
corresponding tumor types or subtypes. For example, a gene ex-
pression analysis of lung tumors and lung cell lines (9) suggested 
that some lung adenocarcinoma cell lines did not resemble adeno-
carcinoma tumors but instead clustered with other lung tumor subtypes 
(small cell and squamous cell tumors). A study of high-grade serous 
ovarian cancer cell lines that used gene expression, driver gene 
mutations, and copy number alteration (CNA) data reported that 
two frequently used cell lines showed poor genetic similarity to 
molecular profiles of this ovarian cancer subtype (12). A study of a 
panel of renal cancer cell lines compared their CNA to kidney 
tumors, finding that some cell lines used as models of the clear cell 
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carcinoma more closely resemble papillary renal cell cancer (13). 
These examples highlight the need to systematically identify the cell 
lines whose genotype and/or molecular phenotypes do not resem-
ble the characteristics of the matched human tumor type. A major 
challenge in the use of human tumor molecular data to classify cell 
lines are the widespread global changes in gene regulation between 
cell lines and tumors that arise in cell culture conditions.
We performed a systematic analysis that aligned mRNA expression 
and DNA methylation data between ~600 cancer cell lines and ~9000 
tumors from 22 different cancer types, adjusting for global differ-
ences in transcriptomes and epigenomes. Classifiers trained on 
human tumor mRNA and DNA methylation profiles were used to 
identify those cell lines whose genomic and epigenomic profiles are 
highly consistent with human tumors of their declared cancer type 
of origin. Conversely, we used the same classifiers to identify those 
cell lines that might be mislabeled with an incorrect cancer type or 
that might have diverged from their original tissue and/or cell type 
identity. Our data suggest that tens of cell lines might be epigenetically 
and/or genetically not consistent with their stated tissue or cell type 
of origin, which is an important consideration for experiments that 
use these cell lines. We demonstrate this by reanalyzing associations 
between drug sensitivity and genetic variation in a large panel of cell 
lines. After explicitly accounting for putative cases of cell lines with 
mislabeled tissue identity, many previously unknown associations 
of genes with drug sensitivity or resistance were revealed.
RESULTS
Identification of tissue/cell type of origin for cell lines by 
a joint analysis with tumors
The tissue that originated a tumor is well known to be a major 
determinant of drug responses, including drugs targeted to specific 
genetic mutations, both in vitro (10, 11) and in vivo (14, 15). Tissue 
of origin is an important factor in shaping the networks of genetic 
interactions in cancer (16), and it also determines the phenotypes 
resulting from genetic perturbation (11). Therefore, ascertaining 
the tissue/cell type identity of cell lines is relevant for interpreting 
results of various experiments. For this reason, here, we have 
systematically examined the global features of the transcriptome 
and epigenome to identify the tissue of origin of tumoral cell lines.
During the process of adaptation to cell culture, the cells under-
go changes in gene regulation that affect many genes (17, 18). The 
global alterations in gene expression and DNA methylation mean 
that it is not straightforward to directly compare cell line transcrip-
tomes and epigenomes with data obtained from tumors. To adjust 
for these cell culture–associated shifts, we introduce a computational 
methodology—HyperTracker—which can unify transcriptome, 
epigenome, and mutational data across tumors and cell lines and 
provide robust predictions of tissue, cell type, and subtype identity.
In particular, we collected gene expression [RNA sequencing 
(RNA-Seq)] and DNA methylation data (microarrays) for 9681 and 
9039 human tumors, respectively (TCGA), and additionally for 
614 cell lines (CL) of various solid cancer types and 69 CL of blood 
tumors. For gene expression data (GE), we examined transcript-per- 
million (TPM) normalized counts for the 12,419 genes, where 
RNA-Seq data could be linked between cell lines and tumors. For DNA 
methylation data (MET), we examined beta values for 10,141 probes 
from methylation arrays after selecting a single probe per gene pro-
moter with the highest variance across the dataset. To align human 
tumor and cell line data, we quantile-normalized the data and applied 
ComBat, a batch effect correction method (19), which is highly 
performant compared to other related methods (20). In brief, ComBat 
estimates parameters for location and scale adjustment of each batch 
(TCGA and CL in our case) for each gene. Then, it removes the 
variability that is particular to the CL but not present in TCGA, 
while retaining the intra-dataset variability of the tumors, which 
should presumably be evident in both the tumor and in the cell line 
datasets.
A principal components analysis (PCA) in the data (before and 
after adjustment) suggests that there were strong global differences 
between TCGA and CL, which are largely removed by our approach 
(Fig. 1A and fig. S1A). To quantify this, we calculated the effect size 
(Cohen’s d statistic) for each gene/probe between TCGA and CL 
before and after adjustment. It can be observed that these differences 
are reduced to the minimum after adjustment (fig. S1C). In addition, 
we trained a classification model that predicts the CL versus TCGA 
origin of the data points based on GE and MET (Fig. 1B and fig. 
S1B). The model is able to distinguish CL versus TCGA perfectly 
when using the preadjustment datasets [area under the receiver 
operating characteristic (ROC) curve (AUC) = 1/area under the 
precision-recall (PR) curve (AUPRC) = 1], while the post-adjustment 
datasets do not perform better than random (~0.5 for AUC and ~0 
for AUPRC), suggesting that the cell type–specific signal has been 
largely removed. Last, we tested the optimal number of features 
(genes/probes) using tumor classifiers and calculating the accuracy 
in the cell line data (table S1A); we selected 5000 features with the 
highest SD for subsequent analyses.
Once the data were aligned, we set out to determine which cell 
lines have tissue identity not matching the declared tissue of origin 
(henceforth, “suspect set”) and, conversely, which cell lines have 
largely retained their tissue identity (henceforth, “golden set”), by 
comparing against a large set of tumors from 17 tissues in the TCGA 
(Fig. 1C). Using TCGA data, we derived one-versus-rest classifica-
tion models (using ridge regression), separately for the GE and the 
MET data. These two data types were used because they yielded 
higher accuracies for the one-versus-rest setting than the four different 
mutation-based classifier types we tested (fig. S1G); the mutation- 
based classifiers were nonetheless useful for subsequent validation 
analyses (see below). Some pairs of cancer types were considered 
jointly based on their overall similarity, for example, stomach 
adenocarcinoma (TCGA code: STAD) and esophageal adenocarci-
noma (subset of samples from TCGA code: ESAD); see Materials 
and Methods for a full list. Our study examines solid cancer types 
and blood cancers in separate analyses.
Differential tumor purity across the TCGA does not have a 
notable bearing on our tissue classification: Accuracies of models 
from higher-purity tumor samples were similar to models from 
other tumor samples (fig. S1D). Moreover, introducing GE data of 
healthy tissues [from Genotype-Tissue Expression (GTEx)] into a 
joint analysis with the TCGA tumor data did not further improve 
the GE classifier (fig. S1F). GE data from healthy tissues, considered 
by themselves, were less informative for assigning cancer cell lines 
to tissues of origin than GE data from tumors (fig. S1E), consistent 
with a tumoral origin of the cell lines.
Next, we obtained predictions of cancer type identity for each 
cell line. For every cancer type, we split TCGA data randomly into 
training and testing sets, and we used the calculated PR curve of the 
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(details in Materials and Methods; all TCGA-derived precision 
score values are listed in table S1, B and C). The higher the precision, 
the more likely the cell line is to belong to that particular cancer 
type. As expected, most of the cancer type labels of the cell lines 
match the declared tissue of origin of that cell line—they tend to 
cluster at high precision values for the cognate cancer type (red dots 
in Fig. 2A and fig. S2). However, among these many correctly clas-
sified cell lines (red dots), there are some with similarly high preci-
sion scores, but which were originally annotated as belonging to 
another cancer type (Fig. 2A, blue dots with labels shown). A cluster-
ing analysis of the GE and MET values for the genes with the highest 
weights in the classification models (Fig. 2B and fig. S3) showed 
that the samples generally cluster by cancer type, but not by CL versus 
TCGA label. Moreover, we observed that the suspect cell lines (i.e., 
cell lines with highly confident precision scores to a different cancer 
type) tend to cluster with the newly assigned cancer type, rather than 
with the original one (Fig. 2B).
In further analyses, we designated as the golden set those cell 
lines that have precision ≥0.7 (see fig. S4 and Materials and Methods 
for threshold selection) for both GE and, independently, MET in 
their originally declared cancer type (n = 366 of 614 examined cell 
lines, 60%). For these cell lines, two independent types of evidence—
transcriptomes and epigenomes—support that they match their 
expected cancer type well, suggesting that these cell lines would be 
preferred experimental models. Further, we designated as the “silver 
set” those cell lines that have precision ≥0.7 for one classifier (either 
GE or MET but not both) (n = 131 of 614, 21%). From the remaining 
117 cell lines, we selected as suspect set those CL that exhibit a pre-
cision of ≥0.7 for both GE and for MET, but for a different cancer 
type than declared for that cell line (n = 43 of 614, 7% of analyzed 
cell lines) (Fig. 2C and fig. S4C). This set of cell lines may consist 
either of mislabeled cell lines, where the cancer type of origin is dif-
ferent than initially thought, or of heavily diverged cell lines, where 
the genomic and/or epigenomic alterations accumulating during 
culture have overridden the original cancer type identity. Notably, 
cell line cross-contamination issues (21) cannot commonly underlie 
the trends we observe, because the repositories that provided GE 
and MET data have used genetic markers to ascertain the identity of 
the cell lines (4). The fact that two classifiers based on independent 
data types—one transcriptomic and one epigenomic—reached the 
same predictions adds confidence that these are bona fide cases of 
mistaken tissue/cell type identity. In case of blood cancer classifiers, 
A B
C
Fig. 1. Methodology for data alignment and cancer type classification. (A) Principal component (PC) 1 and PC2 of a PCA, in the gene expression (GE) data, before 
adjustment for batch effects (raw data) and after adjustment [quantile normalization (QN) + ComBat] [see fig. S1 for PCA of DNA methylation data (MET)]. Colors represent 
the dataset sources (GDSC and CCLE are two sources for the cell line data, and TCGA is the source for the tumor data). (B) ROC curves for classifying tumors versus cell lines 
in the data before adjustment (orange) and after adjustment (blue) for GE and MET. (C) Schematic overview of the HyperTracker methodology. First, we systematically 
identified possible mislabeled cell lines using GE and MET data, independently. Second, we used various types of mutation-based data to corroborate the predictions. 
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which were highly accurate in distinguishing myeloid and lymphoid 
lineages, there were no cell lines suspected to be mislabeled between 
the lineages (fig. S2B).
Validation of individual examples of suspected mislabeled 
cell lines using genomic classifiers
We detected 43 cell lines that bear both transcriptomic and epigenomic 
features of a different cancer type than the one they were originally 
annotated with. We next turned to support individual examples of 
reassigned tissue identity by analyzing independent data. In partic-
ular, we used genomic sequence–based classifiers, which are able to 
predict the tissue of origin based on somatic mutation patterns 
(22, 23), in particular, the trinucleotide mutation spectra and the 
presence of oncogenic mutations and CNA profiles (22, 23). In this 
validation setting, we applied these genomic classifiers to a problem 
of one-versus-one classification, where we contrasted the originally 
assigned cancer type versus the newly proposed cancer type for each 
reassignment. We found that these one-versus-one classifiers based 
on genomic data had satisfactory accuracy with whole-exome 
sequencing (WES) datasets that we used [fig. S5; notably, our recent 
work (22) suggests that whole-genome sequences, when available, 
would provide more powerful classifiers that draw on regional muta-
tion density (RMD) patterns].
For the 43 examples of suspect cell line tissue identity, we first 
derived one-versus-one classification models separately for GE and 
MET and prioritized reassignments that were consistently observed 
across multiple runs of the classification algorithm. We randomized 
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Fig. 2. Detection of cell lines suspected to be mislabeled with a different cancer type. (A) TCGA-based precision scores for 614 cell lines were calculated in the MET 
and GE cancer type classifiers (one-versus-rest) and for 69 blood cancer cell lines. The higher the precision, the higher the confidence that the sample belongs to that 
particular cancer type (here, showing cases of SKCM, KIRC, and CRAD from left to right; see fig. S2 for the other cancer types). The cell lines that were originally annotated 
as the cancer type that is being tested are shown in red, and the rest in blue. (B) Heat map showing the 25 genes (GE) and CpG probes (MET) with the highest absolute 
values of ridge regression coefficients for each of the cancer types in the plot in one-versus-rest classifiers. The suspected skin cell lines are labeled. The cancer types 
shown are the suspected cancer type [melanoma (SKCM) in this case] and, additionally, the originally declared cancer types of the suspected cell lines [here, esophagus 
and stomach cancer (ESTAD), sarcoma (SARC), colorectal cancer (CRAD), and ovarian and uterus cancer (GYNE)]. See fig. S3 for the heat maps for the rest of the suspected 
cell lines. (C) Overview of the results from the systematic mislabeling testing of all cell lines. Cell lines with a TCGA_precision ≥ 0.7 to its original cancer type in (i) both in 
GE and in MET are assigned to the golden set group and (ii) either in GE or in MET are assigned to the silver set. If, however, the TCGA-based precision ≥ 0.7 to a different 









Salvadores et al., Sci. Adv. 2020; 6 : eaba1862     1 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
5 of 15
consistency score for the reclassification (Fig. 3B and fig. S6A). 
From the 43 suspect cell lines, 35 are consistently reassigned to the 
other tissue (score > 10) (Fig. 3A and fig. S6B). Next, we calculated 
the same score for the genomic classifiers (based on mutations and 
CNA, as described above) on these 35 suspect cell lines (Fig. 3A).
Of these, approximately two-thirds (n = 22 cell lines) received 
high support for the new tissue label by one or more genomic 
classifiers [Fig. 3A; consistency score ≥ 15, corresponding to 
randomization-based false discovery rates (FDRs) of 0, 0, and 18% 
for the CNA, OGM, and MS96 classifiers, respectively; Fig. 3B]. 
These data suggest that 22 cell lines are candidates for assignment to 
another cancer type, based on converging evidence from the levels 
of the genome, epigenome, and transcriptome, which provides 
higher confidence. Reassuringly, this list contains two cell lines that 
have been previously shown to be misclassified: SW626, which was 
initially annotated as ovarian cancer but later discovered to be 
derived from colon cancer (24), and COLO741, which was originally 
thought to be a colon adenocarcinoma cell line but later shown to 
originate from a melanoma (25). The fact that these two known 
examples were detected and reassigned to the correct cancer type 
provides evidence that our HyperTracker method is overall reliable.
The two plausible reasons why a cell line thought to originate 
from one cell type would be reassigned to a different cell type are (i) 
that, at the time of isolation, the cell line was not of the type that it 
was thought to be (mislabeling) and (ii) that, during prolonged cell 
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Fig. 3. Additional evidence supporting tissue identity of the suspected mislabeled cell lines. (A) Prediction consistency score (0 to 20) for each suspected cell line 
for 20 runs of one-versus-one classifiers that predicted suspected versus original cancer type in GE, MET, CNA, trinucleotide mutation spectrum (MS96), and oncogenic 
mutations (OGM). A value of 20 means that the cell line is predicted as suspected consistently in the 20 runs of the classification algorithm, and a value of 0 means that it 
is predicted as original cancer type. (B) Histograms of the consistency scores for CNA and MS96 classifiers for the models based on actual data and a baseline expectation 
on randomized data. (C) Prediction scores for MS96 and CNA for the suspected cell lines. Colors represent the suspected cancer type [see column “new” in (A)]. Gray dots 
represent the random values. (D) Drug sensitivity (IC50) for mutant BRAF-targeting drugs dabrafenib and trametinib for 614 cell lines. Cell lines originally labeled as skin 
cancer are shown in turquoise, and skin-suspected cell lines are marked with a square and their name. (E) Burden of UV-associated mutation signature 7 (estimated from 
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cell type (transdifferentiation). Our data allow us to examine how 
prevalent each case is: Mislabeling is expected to be reflected equally 
in both the epigenome and the genome, while transdifferentiation is 
expected to be reflected more strongly in the (presumably more 
malleable) epigenome, and less so in the genome, which retains the 
mutations from the original tumor. We suggest that mislabeling at 
isolation is a much more common scenario (Fig. 3C, many reassigned 
cell lines are in the upper right corner). However, it is possible that 
there exist individual examples of cell lines that have effectively 
transdifferentiated during culture, because their genomic features 
are consistent with the original tissue identity, while the epigenomic 
features are consistent with another tissue (Fig. 3C, lower left corner; 
e.g., the RPMI2650 and OACM51 cell lines are possible candidates).
Validation of cell lines suspected to originate from the skin
From the previous analysis, we identified six cell lines that are reas-
signed from various cancer types to skin cancer. We note that, of 
skin cancers, the TCGA study contains only melanoma but not the 
nonmelanoma skin cancers, so we were not able to distinguish 
between cell type identities of different skin cancers.
To further support that these cell lines are skin cells, we performed 
an independent analysis based on mutational signatures. Large-scale 
analyses of trinucleotide mutation spectra across human tumors 
have revealed at least 30 different types of mutational signatures 
(26). Of these, signature 7 (C>T changes in CC and TC contexts) 
was associated with exposure to ultraviolet (UV) light and is highly 
abundant in sun-exposed melanoma tumors (27). The same signa-
tures were recently estimated in cancer cell lines (28, 29), which 
enabled us to use the existence of UV-linked signature 7 to examine 
whether these cell lines originated from the skin. On the basis of 
mutational burden of signature 7, the known melanoma cell lines 
are clearly separated from the rest (Fig. 3E), meaning the approach 
can distinguish skin-derived cells. Among the melanoma cell lines 
with high mutational burden of signature 7, we found four of five of 
the suspected cell lines (Fig. 3E), in particular, GCT, SW684, ES2, 
and MDST8 are very likely skin cell lines, and not sarcoma, sarcoma, 
ovarian cancer, or colorectal cancer, respectively, as originally thought. 
For the sixth suspected cell line COLO741, the mutational signature 
data are not available; however, COLO741 has previously been 
reported to express skin-specific genes (25).
The RF48 cell line (originally considered stomach, here putatively 
reassigned to skin) does not exhibit the UV signature or the DNA 
methylation patterns of skin; therefore, a highly confident call cannot 
be made. Nonetheless, a pattern of cancer driver mutations in RF48 
suggests that it is not a stomach cell line (Fig. 3A). Previous work 
based on gene expression proposed a lymphoid origin for RF48 (30).
Next, we sought to substantiate these findings using drug sensi-
tivity data. In particular, two drugs (dabrafenib and trametinib) that 
target mutant BRAF are approved for treating melanoma in the 
clinic. These drugs are known to have poor efficacy in other cancer 
types bearing BRAF mutations, such as in colon cancers (31). 
Therefore, sensitivity to these drugs adds confidence that we are 
looking at a melanoma cell line (note that the converse does not 
necessarily hold here: resistance does not imply that the cell line is 
not a melanoma). Therefore, we compared the median inhibitory 
concentration (IC50) of these two drugs for all cell lines (Fig. 3D). As 
expected, many melanoma cell lines cluster at low values of IC50 for 
the two drugs, meaning that these cells are sensitive to the drug. 
This includes two of five of our suspected cell lines (ES2 and 
MDST8), providing further supporting evidence that these are of 
skin, likely melanoma, origin.
In conclusion, out of six cell lines suspected to originate from 
skin, four were confirmed by the UV mutational signatures and 
two were additionally confirmed by the drug sensitivity to BRAF/MEK 
(mitogen-activated protein kinase kinase) inhibitors. This notable 
example demonstrates how the transcriptome- and epigenome-based 
tissue/cell type classifiers are able to link cultured human cell lines 
with their correct cancer type of origin.
In addition to these examples of skin cell lines, we were able to 
support several other cancer type reassignments using drug sensi-
tivity (results are summarized in table S1D) (32). The DANG cell 
line is consistent with squamous cell carcinoma of the lung or of the 
head and neck (SCC), rather than with its original assignment of 
pancreatic adenocarcinoma (notably, this reassignment is also ob-
served with multiple genomic classifiers; Fig. 3A). Similarly, SW1710 
may be a kidney, rather than a bladder, cell line, based on the original 
reassignment via transcriptome and epigenome, supported by the 
mutation patterns (Fig. 3A) and additionally supported in the global 
analysis of drug responses (table S1D). We note that such analyses 
of drug screening data can be applied to distinguish only certain 
pairs of tissues and not all reassignments can be reliably validated in 
this test (see AUC scores in table S1D).
Identification of subtypes for cell lines using  
multi-omics analyses
Tumors are heterogeneous, and major differences exist between 
tumor samples of the same cancer type. To manage this variability, 
cancer types are subdivided on the basis of their molecular charac-
teristics, including global patterns in gene expression and DNA 
methylation (33–35). However, with the exception of a few tumor 
types, prominently breast cancer, molecular subtypes are still being 
established or refined, often with the goal of better predicting 
disease progression in response to particular treatments. Because 
drug screens and genetic screens performed on cell line panels have 
the goal of serving as models for actual tumors, it is useful to be able 
to transfer the subtype assignments from tumors to cell lines, thereby 
establishing which cell lines are the most appropriate model for 
each cancer subtype.
Previously, molecular subtypes from tumors have been inferred 
in cell lines using different strategies, often based on gene expres-
sion, for example, in breast (36), colorectal (37), and renal cancer 
(13). In a recent pan-cancer study, subtypes have been assigned to a 
set of 600 cell lines (38).
Our approach to assign subtypes to cell lines is to apply the same 
strategies that yielded accurate cancer type classifiers: first, the inte-
gration of transcriptomic and epigenomic data to boost confidence 
in the predictions, and second, careful adjustment of the datasets to 
make them comparable between TCGA tumors and cell lines (fig. S1). 
An important consideration here is the lack of known labels needed 
to assess accuracy; thus, assignments should be treated as tentative. 
However, for breast cancer cell lines, the subtype labels are available 
and can be used as a benchmark (36).
We examined subtypes proposed for 15 cancer types in the 
TCGA and generated subtype classifiers (see Materials and Methods) 
for each cancer type. The combination of both data types (GE and 
MET) achieved a higher cross-validation accuracy in the TCGA 
(median AUPRC across cancer types: 0.81) than GE (0.76) or MET 
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generate subtype classifiers and propose assignments of the cell 
lines to cancer subtypes. Most were uniquely assigned to a single 
subtype (fig. S7A); we used only those in further analysis. As a 
benchmark, we calculated the accuracy for the breast cancer cell 
lines with subtypes available (fig. S7B): The median AUPRC across 
subtypes for CL is 0.83. This suggests acceptable performance in 
obtaining tentative subtype assignments for cell lines in all 15 cancer 
types, which we provide in table S1E. This resource is complemen-
tary to a recent set of subtype predictions for nine cancer types 
based on transcriptomes (38).
Next, we examined whether the relative prevalence of subtypes is 
similar between tumors and cell line panels of the same cancer type. 
Cell line panels of some cancer types have good representation of 
subtypes, for instance, lung squamous cell cancer, head and neck 
squamous cell cancer, lung adenocarcinoma, and gastric/esophageal 
cancers (fig. S7C). However, the converse is the case for liver, skin, 
and thyroid cancer cell lines, where a single subtype predominates 
in cell line panels, unlike in tumors (statistics are listed in table S1F). 
In addition, we observe suboptimal representation (half of the 
tumor subtypes are not represented) in the kidney, bladder, and 
brain cancer cell line panels, when considering the 463 cell lines we 
analyzed. This suggests that, in some cancer types more than others, 
the commonly used cell line panels do not represent the diversity of 
molecular subtypes in tumors well. One possible reason for this is 
the relative ease of culturing certain subtypes compared to others (2).
Accounting for mislabeled cell lines reveals associations 
in drug screening data
We detected 35 cell lines that may have a tissue or cell type identity 
different than the one originally assigned to them. Because the cell 
type is an important determinant of drug response in cancer cell 
lines and in tumors (10), we hypothesized that the inclusion of this 
new tissue information when searching for genetic determinants of 
drug sensitivity may change the results. In a comprehensive study, 
Iorio et al. (10) searched for associations between drug response 
and cancer functional events (CFEs): recurrent mutations, CNA, 
and hypermethylation events present in human tumors. Here, we 
used GDSCTools (39) to reproduce the results of that study, however, 
after filtering the cell lines to those that better represent the cancer 
type in question. In particular, we repeated the same analysis using 
for each tissue (i) all the cell lines, (ii) only the cell lines in the golden 
set (G), and (iii) as a less stringent filtering criterion, only the cell 
lines in the golden set and silver set (G&S). In addition, as controls, 
we included a random subset of cell lines that matches (iv) the number 
of cell lines in golden set (r_G) and (v) the number in “golden and 
silver set” combined (r_G&S).
For most of the cancer types, we observed that one of the filtered 
subsets recovered a higher number of significant [at FDR ≤ 25%, as 
applied in the original study (10)] associations of CFE with drug 
sensitivity or resistance than were recovered using all cell lines (fig. 
S8A and table S1G). For instance, for glioblastoma, using the golden 
set cell lines, we found 23 associations, which were not recovered 
from the entire cell line panel or from the random subset controls 
(Fig. 4B). For example, this recovers the positive association of 
CDKN2A loss with camptothecin sensitivity (Fig. 4C), which was 
previously reported in an independent analysis of the NCI-60 cell 
line panel screening data (40). Similarly, for pancreatic adenocarci-
noma, benefits were observed by focusing on cell lines that resemble 
the corresponding cancer type better: Using only the golden set plus 
silver set cell lines, 10 significant, previously unknown associations 
were found (Fig. 4B). For instance, we detected that SMAD4-mutant 
cell lines are more resistant to piperlongumine, a natural product that 
exerts antitumor properties via multiple pathways (41). Mutations 
in the tumor suppressor gene EP300 were associated with higher sen-
sitivity to three drugs in pancreatic cancer cell lines (Fig. 4D). The 
observation that more associations were found despite using a 
somewhat lower number of cell lines (thus less statistical power) 
emphasizes the importance of focusing on the cell lines that more 
closely model the tissue and/or cell type of origin of the cognate tumor.
Colorectal cancer provides an illustrative example of the impor-
tance of removing nonrepresentative cell lines from drug screening 
efforts. In the original study (10), 50 colorectal adenocarcinoma 
(CRAD) cell lines were tested. Of those, we strongly suspected that 
MDST8 derives from skin. To test the influence of this individual 
mislabeled cell line, we have performed association testing with all 
colorectal cell lines and again after excluding MDST8. For the asso-
ciation between dabrafenib response and BRAF mutation status, we 
observed that CRAD cell lines in general (i.e., irrespective of BRAF 
mutation) are not sensitive to dabrafenib, except for MDST8, which 
is strongly sensitive to dabrafenib (Fig. 4A). The FDR of the analysis 
of variance (ANOVA) analysis when using all (allegedly) colorectal 
cell lines is significant at 6%, while when removing MDST8 the FDR 
for BRAF-dabrafenib association in colon becomes nonsignificant 
(45%). Therefore, in this case, the presence of a single mislabeled 
cell line is sufficient to cause the appearance of an association 
between a drug and a feature, which is likely not relevant for this 
cancer type. This is evidenced in the clinical responses of patients: 
BRAF-mutant melanoma patients respond well to dabrafenib, while 
colorectal tumors with the same BRAF V600 mutation are not 
sensitive to BRAF or MEK inhibitor monotherapy (31).
Accounting for mislabeled cell lines in genetic screening 
data analyses
Motivated by the associations revealed by reanalyzing the drug 
screening data, we asked whether the same extends to genetic 
screening data in cancer cell lines, because results in genetic screens 
also depend on cell lineage (11). To further investigate, we analyzed 
CRISPR screening data from Project Score and Project Achilles (see 
Materials and Methods), from which 347 cell lines overlap our tested 
cell lines. Then, we applied the same association testing method, 
which was, however, underpowered, because the number of avail-
able overlapping cell lines was smaller. Nonetheless, in colorectal 
and ovarian cancer (which have the largest number of cell lines in 
this dataset), we observed that by focusing only on the golden set 
and/or silver set, the number of recovered associations increased 
(as a control, there were no increases in randomly chosen cell line 
subsets of the same size; fig. S8B and table S1H).
To illustrate the importance of removing suspect cell lines in 
gene dependency screenings, we provide two examples of associa-
tions that were originally not significant because of the presence of 
a mislabeled cell line. For ovarian cancer, the presence of SW626 
[mislabeled cell line confirmed by the literature (24)] prevents find-
ing the association between MED8 dependency and a copy number 
gain in the region containing ASXL1 [“cnaOV72” in (10)] as signifi-
cant (fig. S9A). Similarly, for colorectal cancer, the presence of 
MDST8 (mislabeled cell line confirmed by the UV mutational 
signature) prevents detection of the association between TUBB4B 
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(“cnaCOREAD32”) (fig. S9B). Next, a significant association between 
WRN dependency and MLL2 (also known as KMT2D) gene muta-
tion is recovered only with the filtered cell lines in ovarian cancer 
(fig. S9C). This WRN-MLL2 association has been recently reported 
using a different set of cell lines (from Project Score) (42) that par-
tially overlap our set.
Last, our reanalyses of drug screening and genetic screening data 
revealed an interesting association independently supported in 
both drug and genetic data. The drug afatinib inhibits the epidermal 
growth factor receptor (EGFR) protein and is clinically indicated 
for EGFR-mutated lung cancer; however, in EGFR-altered glioblas-
toma, afatinib is generally not considered to elicit a response (43). 
Consistently, afatinib sensitivity was associated with EGFR alterations 
in lung cancer previously (10), as well as in our reanalysis (FDR lung 
G&S sets = 0.6%), but not in the brain cell line panel (all cell lines, 
FDR ≥ 25%). However, using the focused (golden set) of brain cancer cell 
lines revealed a significant association (ANOVA FDR = 15%; fig. S9D) 
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Fig. 4. Drug sensitivity association testing using high-confidence sets of cell lines. (A) Drug sensitivity (IC50) to dabrafenib in all colorectal (CRAD) cell lines (left) and 
all CRAD cell lines except MDST8 (right), which is suspected of being skin cancer. Cell lines with a BRAF mutation and without (wild type) are compared. ANOVA FDR for 
this association (dabrafenib sensitivity with BRAF mutation status) is shown in blue for both datasets. Horizontal line is shown at 0, because score < 0 implies sensitivity to 
the drug. Dots and error bars represent the mean and SEM. (B) Number of significant associations between “CFEs” (includes mutations and CNAs in cancer genes) and 
drug associations detected (at FDR 25%) in the ANOVA test for all cell lines (“all”), cell lines in the golden set (“G”), cell lines in the golden plus silver sets (“G&S”), random 
subset of cell lines that match the number in the golden set (“r_G”), and random subset of cell lines that match the number in the golden plus silver sets (“r_G&S”). For the 
random subsets, the number of significant associations is calculated from 10 random selections and median shown. P values for a sign test (one-tailed) between the 
number of associations in the G/G&S and in r_G/r_G&S are shown. See fig. S7 for the remaining cancer types. (C) Differential sensitivity of drugs was analyzed by ANOVA 
for all brain cancer cell lines (left) and the brain cancer cell lines in the golden set only (right). Each point is an association between the sensitivity of a drug and a genetic 
feature (CFE). (D) Differential sensitivity of drugs was analyzed by ANOVA for all pancreatic (PAAD) cell lines (left) and PAAD cell lines in the golden and silver set only 
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number loss in a region at 1p32.3 containing the CDKN2C and 
FAF1 genes [“cnaGBM68” in (10)]. The same loss at 1p32.3 is asso-
ciated with sensitivity to genetic knockout of EGFR in brain cell line 
panels in two independent large-scale genetic screens (Project Scores 
and Project Achilles; fig. S9, F and G) and to pharmacological inhibi-
tion in another drug screen (PRISM; fig. S9E). The meta-analysis of the 
two drug screens and two genetic screens suggests high strength 
of combined evidence (P = 0.00094, Fisher’s method of combining 
P values) linking the CNA loss at 1p32.3 (chr1: 51169045-51472178) 
with sensitivity to pharmacological or genetic EGFR inhibition in 
brain cells, suggesting a candidate marker for follow-up work.
In summary, the presence of cell lines with dubious or incorrect 
labels of tissue identity may strongly affect association studies of 
drug or CRISPR screening data in two different ways. First, the 
presence of mislabeled cell lines can cause the appearance of spurious 
associations that do not reflect the biology of the cancer type of 
interest. Second, the presence of mislabeled or divergent cell lines 
can prevent the recovery of true associations.
DISCUSSION
Cell lines are commonly used as models for tumors; however, it is 
an open question how to best apply the available cell line panels to 
learn about cancer biology. The availability of genomic data from 
large tumor cohorts and from cell line panels has spurred efforts to 
find which cell lines are closer to tumors by their transcriptomic 
(9, 37, 38) and/or genomic features (12, 13), presumably making better 
models, and which are more distant from examples of actual tumors, 
thus making less good models.
Our work addresses a different question: We attempt to detect 
the cancer type (i.e., tissue and/or cell type) that originated the cell 
line to ascertain whether this matches the declared origin of the cell 
line. A mismatch may conceivably stem from the sampling step, for 
instance, a metastasis might have a different tissue of origin than 
thought at the time of surgical collection. The work-up after collecting 
the tumor sample may have inaccurately assigned the cancer type, 
based on unclear histological or anatomical features. Another possi-
bility is that the mismatch might stem from the step of adaptation to 
cell culture, where a minority cell type that is not representative of 
the tumor prevails over other tumoral cells. We consider these to be 
cases of cell line mislabeling during isolation. In addition, we would 
also detect cases where the cell line might have acquired some prop-
erties of a different tissue/cell type during extended periods in culture; 
however, our analyses (Fig. 3C) suggest that this is a less common 
occurrence, although individual examples cannot be ruled out.
This phenomenon of tissue/cell type mislabeling is distinct from 
well-known and widespread cell line misidentification issues (21), 
where one cell line (often HeLa) was mistakenly used in place of 
another cell line originating from a different individual, commonly 
due to cross-contamination. The cell line panels that provided data 
used in our analyses (GDSC and CCLE) have authenticated their 
cell lines (4, 42); thus, misidentification/cross-contamination cannot 
underlie our observations of mislabeling of the cancer type of origin. 
[We note that there were rare cases of misidentified cells reported in 
these panels (42); however, these do not overlap our results.]
Methodologically improving over previous work, we introduce 
the HyperTracker framework that performs global analyses, which 
independently examine transcriptomic, epigenomic, and mutational 
features. In addition, we carefully adjust for the known bulk dif-
ferences between cell lines and tumors, which might have resulted, 
e.g., from impurities in tumors or from altered expression of cell 
cycle–related genes in cell lines (38). Parallel analyses of different 
omics data provide increased confidence in our inferences, which 
suggested, remarkably, that 5.7% (35 of total 614 considered cell 
lines) exhibit significant transcriptomic and epigenomic features of 
a different tissue/cell type than the declared cell type of origin. For 
3.6% (22 cell lines), these reassignments to a different cancer type 
were additionally supported in at least one type of genomic evidence. 
This increased confidence that these were examples of cell lines 
with mislabeled (or, less likely, diverged) tissue/cell type identity. 
Notable examples are cell lines GCT, SW684, ES2, and MDST8 that 
we predict to originate from the skin, based on the presence of 
the UV mutational signature, in addition to strong evidence in 
transcriptome/epigenome data. These cases are reminiscent of the 
recent reports of UV mutational signatures found in some cases of pre-
sumed lung cancers, suggesting that they may instead be metastases 
originating from sun-exposed skin (44).
In interpreting our data, an important consideration is that the 
cancer sample types in TCGA may not necessarily reflect the full diver-
sity of rarer subtypes within a cancer type, which may cause some 
ambiguous predictions. For instance, the ECC10 and ECC12 cell lines 
are assigned to STAD cancer type (stomach adenocarcinoma) when 
matched with TCGA tumors. These cell lines originate from gastric 
small cell neuroendocrine carcinomas. This might explain why, in our 
analysis, gene expression patterns point toward brain tissues, while 
mutational features suggest stomach cancer. In such cases of disagree-
ment between different types of features, a future use of a more ex-
haustive set of reference tumor data, which includes rarer cancer types, 
may resolve the ambiguity and improve confidence in predictions.
The genomic classifiers we used here were based on whole-exome 
sequences and were overall less powerful than the transcriptome/
DNA methylation classifiers in our data (figs. S1G and S5). Recent 
work by us and others (22, 23) suggest that analyzing whole-genome 
sequences of these cell lines would permit use of additional, highly 
predictive features based on RMD of chromosomal domains. This 
may provide further genomic evidence for the identity of the cell of 
origin for the 35 suspected cell lines. Furthermore, targeted experi-
mental follow-up work on these cell lines will provide further 
evidence to support or refute our predictions, which are based on 
global, multi-omics analyses.
Knowing the correct tissue-of-origin label for a cell line is im-
portant, because this has a strong bearing on the response of the cell 
line to drug treatment and to genetic perturbation. We demonstrate 
the implications of this general principle to analyses of drug and 
genetic screening data: By accounting for suspect cell lines, the power 
to discover determinants of sensitivity to pharmacological and to 
genetic perturbation may increase substantially for some cancer 
types, such as brain, lung, and pancreatic cancers. Therefore, when 
designing future screening efforts, it is important not only to increase 
the number of cell lines to gain more power but also to focus on the 
cell lines that best reflect the tissue and/or cell type of interest.
MATERIALS AND METHODS
Omics data collection and preparation
DNA methylation data
We downloaded DNA methylation data as beta values (platform: 
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for TCGA samples and from GDSC (3) for CL samples. We filtered 
out all probes outside promoter regions and probes with not avail-
able (NA) values in more than 100 samples. For the probes in pro-
moter regions, we selected only one probe per gene that had the 
highest SD across samples. We transformed the beta values to m-values 
(log2 ratio of the intensities of methylated probe versus unmethylated 
probe). In total, this yielded 10,141 features for 942 CL samples 
and 8453 TCGA samples.
Gene expression data
We downloaded gene expression data as TPM from GDC Data 
Portal (45) for TCGA samples, from GDSC (3) and the CCLE (4) 
for CL samples, and from GTEx Portal for healthy data. We filtered 
out genes with NA values in more than 100 samples and selected the 
overlapping genes between the four sources. We removed low 
expressed genes (TPM < 1 in 90% of the samples) and applied a 
square-root transformation to the TPM data. In total, we have 
12,419 features for 942 CL samples and 9149 TCGA samples.
For both DNA methylation (MET) and gene expression (GE), 
we created datasets of different sizes: 1000, 2000, 3000, 5000, and 
8000 features by selecting the genes/probes with the highest SD 
across TCGA samples. In addition, we downloaded tumor purity data 
from Aran et al. (46) and used consensus measurement of purity 
estimations (CPE) for creating the groups of high- versus low-purity 
samples. High-purity samples were defined as CPE > 0.75, and for 
the lower-purity group, we took a subset of samples (same number 
of samples that are in high-purity subset) with the lowest purity.
CNA data
We downloaded CNA data (computed by gene) from GDC Data 
Portal (45) for TCGA samples and from DepMap (47) for CL sam-
ples. In total, we have 20,491 features for 942 CL samples and 9188 
TCGA samples. To reduce the dataset, we selected CNA events in 
299 known cancer driver genes (48).
Mutation data
For human tumors, we downloaded mutation data as WES MC3 
dataset (49) from the GDC Data Portal for TCGA samples. For cell lines, 
aligned short reads (bam files) were obtained from the European 
Genome-phenome Archive (ID number: EGAD00001001039). Variant 
calling was performed using Strelka (version 2.8.4) with default pa-
rameters. Variant annotation was performed using ANNOVAR 
(version 2017-07-16). In samples where Strelka was unable to run, a 
realignment was performed using Picard tools (version 2.18.7) to 
convert the bams to FASTQ, and following that, the alignment was 
performed by executing bwa sampe (version 0.7.16a) with default 
parameters. The resulting bam files were sorted and indexed using 
Picard tools. To account for germline variants, we removed all 
mutations that were present in the gnomAD v2.1.1 database (50) at 
an allele frequency of ≥0.001 in any of the populations. Last, using 
the filtered somatic mutations, we calculated three sets of mutational 
features: RMD, mutation spectra (MS96), and oncogenic mutations 
(OGM) as described by Salvadores et al. (22). RMD features did not 
exhibit high accuracy when applied to exome-sequencing data and 
so were not considered further in this analysis.
For the cell line samples, we matched their cancer types to the 
TCGA cancer types using the cell line metadata from GDSC (3) and 
manually annotated those that did not have a TCGA cancer type 
label using Cellosaurus (51). Next, we selected the cell lines from 
solid tumors that had a matching cancer type in TCGA, yielding a 
total of 614 cell lines from 22 cancer types. Blood cancers (LAML 
and DLBC) are tested separately, because the cell lines there 
commonly grow in suspension, making them less likely to be 
confounded with solid tumors. For further analysis, we merged the 
cancer types that were overall similar: HNSC with LUSC and ESCC 
(jointly known as SCC), GBM with LGG (LGGBM), STAD with 
ESAD (ESTAD), and OV with UCEC (GYNE).
The identification of the cell line samples was performed by the 
laboratories generating the cell line databases, using short tandem 
repeat analysis (4, 42). They reported a few commonly misidentified 
cell lines: Ca9-22, RIKEN, MKN28, KP-1N, OVMIU, and SK-MG-1 
(42). These cell lines do not overlap with our suspected samples, and 
additionally, the misidentification does not affect tissue or cancer 
type of origin.
Data alignment between tumors and cell lines
For the alignment of TCGA and CL data, we first applied quantile 
normalization (R package preprocessCore 1.46.0) and next applied 
ComBat (R package sva 3.32.1), a batch effect correction method. 
We used ComBat as if our dataset was the TCGA and CL data com-
bined, and the batch effects labels were whether a sample belongs to 
TCGA or CL (for MET) or a sample belongs to TCGA, GDSC, or 
CLLE (for GE). We applied this method for GE, MET, CNA, MS96, 
and RMD. For validation, we calculated a PCA, subsampling TCGA 
data to match the number of CL samples (stratified by cancer types). 
In addition, we calculated Elastic Net classifiers to predict (in the 
processed dataset) TCGA versus CL and calculated the AUC and 
AUPRC to check whether the process of alignment is being successful 
or not. In addition to the chosen adjustment method, we tested other 
approaches based on canonical correlation analysis, partial least 
squares, and PCA, which did not exceed accuracy of ComBat and 
therefore were not examined further.
Cancer type classifiers
For the TCGA dataset, we generated ridge regression model for pre-
dicting the cancer type in a one-versus-rest manner (using cv.glmnet 
function with alpha = 0 and family = binomial, R package glmnet 
2.0.18). To calculate the accuracy, we trained classifiers in the TCGA 
dataset and tested in the CL dataset. In particular, we calculated the 
AUC and the AUPRC for each cancer type versus the rest (all the 
rest of cancer types combined).
TCGA_precision score
For each cell line, we calculated a TCGA_precision score of belong-
ing to a particular cancer type. For this, we divided the TCGA data 
into two datasets (training and testing) of the same size, keeping the 
cancer type proportions. For each cancer type, we trained classifiers 
in the TCGA training dataset, and we introduced the cell lines one 
by one with the testing data and calculated the PR curve (TCGA 
testing + 1CL). We set the cell line precision score for that specific 
cancer type as the precision at the threshold where the cell line is 
situated in the PR curve. Overall, for every cell line, we obtained 
17 precision scores, 1 for each possible cancer type. We repeated 
this procedure five times and calculated the median precision for 
every case to get more robust values. In addition, when training for 
one cancer type (label = 1) versus the rest of cancer types combined 
(label = 0), we made some exceptions and removed those cancer 
types that are similar, and therefore, the classifier is not good at separat-
ing them (e.g., when we calculated precision for ESTAD, we removed 
from the rest CRAD and PAAD, all hidden cases in table S1I). This 
is conservative with respect to reassigning cell lines to another cancer 
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closely related cancer types are, by design, not distinguished. We 
have further attempted to reclassify cell lines within these hidden 
tissues and the combined ones. However, when using one-versus-one 
classifiers, the accuracy is not good enough for distinguishing the 
two cancer types in the cell lines. We selected TCGA-based preci-
sion score ≥ 0.7 as a threshold to separate the different sets (golden, 
silver, and suspected sets), because this cutoff value approximately 
maximizes the F1 score for cell line classification (fig. S4A). At the 
TCGA-based precision threshold ≥0.7, the FDRs estimated on the 
original cell line labels for gene expression and DNA methylation 
classifiers would be 28 and 22%, respectively (fig. S4A); because the 
original labels are not always correct, these FDR estimates are con-
servative. Also, by visual inspection of the distribution densities of 
putatively correct predictions (originally labeled as the matching 
cancer type) and putatively incorrect predictions (originally labeled 
as another cancer type) for cell line tissue labels, one can appreciate 
how a TCGA_precision ≥70% threshold separates well the two 
groups (fig. S4B).
Once we have a list of suspected cell lines, we have an “original” 
cancer type and a “suspected” cancer type. Therefore, we generated 
one-versus-one classifiers (original versus suspected) using TCGA 
dataset (balancing the classes), and for each suspected cell line, we 
checked whether it is predicted as original or suspected. We repeated 
this prediction 20 times and counted the number of times a cell line 
is predicted as suspected. Therefore, we defined a consistency score 
(range between 0 and 20) for every cell line, where 0 means never 
predicted as suspected and 20 always predicted as suspected. As a 
control, we repeated the same procedure with randomized cancer 
type labels, providing estimates of false discovery for different con-
sistency score thresholds (Fig. 3B and fig. S6A). We calculated this 
prediction score for GE, MET, CNA, OGM, and MS96 datasets. For 
calculating the FDR at a score ≥ 15, we applied the following for-
mula: FDR = FP/(FP + TP), where FP is the number of cell lines 
with score ≥ 15 in the randomized data and TP is the number of cell 
lines with score ≥ 15 in the actual data.
Independent validation
We downloaded drug sensitivity for the CL from the GDSC 
database (3). From the provided drugs, we selected trametinib and 
dabrafenib, U.S. Food and Drug Administration–approved drugs 
for melanoma treatment. We compared IC50 values for these two 
drugs for all cancer types.
We downloaded mutational signatures from cell lines available 
from Jarvis et al. (29) and Petljak et al. (28), and we compared the 
exposures of all cell lines for signature 7 (UV light). In Petljak et al. 
dataset, signature 7 is divided into signature 7a, b, c, and d. Therefore, 
we used the sum of exposures across all four subtypes of signature 7.
We downloaded another set of drug screening data (PRISM 19Q3) 
(32) for the CL dataset. For the suspected cell lines, we generated 
one-versus-one classifiers (using cv.glmnet function with alpha = 0 
and family  =  binomial, R package glmnet 2.0.18) for predicting 
original versus suspected cancer type, based on the drug sensitivity 
data. We performed 20 runs of each case and counted how many 
times it is predicted as suspected (consistency score, which can vary 
from 0 to 20). In addition, we calculated the AUC for each classifier.
Subtype classifiers
We downloaded cancer subtypes for the TCGA samples from the R 
package TCGAbiolinks 2.12.6, which comprises many available 
molecular subtype classifications that have been described by 
TCGA-related publications [mRNA, DNA methylation, protein, 
miRNA, CNA, integrative (iCluster), and others]. From those, we 
selected the “subtype_selected,” which is the classification that was 
chosen as the representative one in that cancer type (usually mRNA 
or integrative; see documentation of PanCancerAtlas_subtypes func-
tion for the complete list). We combined the GE and MET datasets 
to predict subtypes. For these data, we generated ridge regression 
model for predicting the subtypes in a one-versus-rest manner 
(using cv.glmnet function with alpha = 0 and family = binomial, 
R package glmnet 2.0.18) within each cancer type. We trained models 
in TCGA, and we predicted subtypes for the cell lines. In addition, 
we used cell line’s subtypes for breast cancer from a previous paper 
(36) to calculate the confusion matrix and the AUPRC.
We performed a chi-square test (R package stats 3.6.0) and 
calculated the Cramer’s V statistic (R package lsr 0.5) for checking 
whether the proportion of subtypes between TCGA and CL is main-
tained for each cancer type.
Drug and CRISPR screening data
We downloaded drug sensitivity and CFE data from Iorio et al. (10). 
CFEs are a collection of recurrent mutations, CNA, and hypermethyla-
tion events present in human tumors (10). We used GDSCTools 
(39) to search for associations between the drugs and the CFEs in 
every cancer as they did. In particular, we performed this analysis 
using for each tissue (i) all the cell lines, (ii) only the cell lines in the 
golden set (G), and (iii) only the cell lines in the golden and silver set 
(G&S). In addition, as controls, we included a random subset of all 
cell lines matching (iv) the number of cell lines in the golden set 
(r_G) and (v) the number in golden and silver set combined (r_G&S). 
We counted the number of significant hits (at FDR ≤ 25%) for each 
of the cancer types. For the controls, we repeated the subsampling 
10 times and took the median of significant hits. We compared the 
number of hits for all the cell lines (same as in Iorio et al. study) with 
the number of hits for the different subsets of cell lines according to 
our grouping. In addition, we performed a sign test (R package 
BSDA 1.2.0) comparing the significant hits in the G/G&S subsets versus 
the significant hits over 10 runs in the random G/random G&S and 
calculated the P value for all cancer types (alternative = “less”).
Similarly, we downloaded gene dependency data from Project 
Score (42) and Project Achilles (52) processed with the Project 
Score pipeline and combined them. From a total of 696 unique cell 
lines, 357 overlap with the 614 cell lines tested with our method. For 
those 357 tested cell lines, we repeated the same procedure as de-
scribed above for the drug sensitivity data.
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